← Human Trials & Peer-Reviewed Studies
Survey of fear and compliance of Insulin Degludec and Insulin Aspart injection in type 2 diabetes mellitus patients and analysis of influencing factors
Plain-language guide to PMID 39533598 (2024): observational study of Insulin Aspart in 120 patients.
Key Facts
- PMID
- 39533598
- Journal
- Medicine
- Year
- 2024
- Study type
- Observational Study
- Authors
- Xie M et al. (3 authors)
- DOI
- 10.1097/MD.0000000000040286
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Insulin Aspart, published as an observational study.
This study aims to investigate the fear and compliance of Insulin Degludec and Insulin Aspart (IDegAsp) injection in type 2 diabetes mellitus (T2DM) patients and study the factors influencing patient compliance.
Why It Was Studied
A total of 120 patients with T2DM treated from February 2019 to March 2022 were investigated and analyzed for fear and compliance on the Diabetes Fear of Injecting and Self-testing Questionnaire of diabetic patients and were divided into compliance and noncompliance groups according to the results to analyze the factors affecting patient compliance.
The study found a high level of fear of IDegAsp injection among the 120 T2DM patients, with an average Diabetes Fear of Injecting and Self-testing Questionnaire score of (39.19 ± 4.59) points.
Who Took Part
The abstract describes 120 patients taking part.
By PubMed's age tags, the people studied were adults, middle-aged adults and older adults, both men and women.
What Was Measured
A total of 120 patients with T2DM treated from February 2019 to March 2022 were investigated and analyzed for fear and compliance on the Diabetes Fear of Injecting and Self-testing Questionnaire of diabetic patients and were divided into compliance and noncompliance groups according to the results to analyze the factors affecting patient compliance.
The study found a high level of fear of IDegAsp injection among the 120 T2DM patients, with an average Diabetes Fear of Injecting and Self-testing Questionnaire score of (39.19 ± 4.59) points.
The subject headings attached to it are Diabetes Mellitus, Type 2, Fear, Insulin, Long-Acting, Hypoglycemic Agents, Medication Adherence, Surveys and Questionnaires and Insulin Aspart.
What This Means in Plain Language
This is an observational study of Insulin Aspart in 120 patients.
The publication is from 2024 (Medicine), a journal based in United States.
More context: the Insulin Aspart compound page, all human trials.
Our Notes on the Compound
Insulin Aspart: A rapid-acting mealtime insulin analog; brands include NovoLog, NovoRapid and Fiasp.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.